Results 111 to 120 of about 12,523 (206)

929Comparison of Echinocandin vs Amphotericin B Based Therapy for Candida Infective Endocarditis: An Observational Cohort Study

, 2014
929Comparison of Echinocandin vs Amphotericin B Based Therapy for Candida Infective Endocarditis: An Observational Cohort ...
Jacob Strahilevitz (520952), Melissa Johnson (1320174), Suzanne Bradley (4734816), Efthymia Giannitsioti (368374), Vivian Chu (2288665), Pierre Tattevin (95746), Denis Spelman (210977), Christopher Arnold (1663705), Cristiane Lamas (6080489), Nuria Fernandez-Hidalgo (19214824), Eugene Athan (13059501), Francisco Nacinovich (19214827)   +11 more
core  

Functional Genomic and Chemical Biology Analysis of Echinocandin Resistance in Candida albicans

, 2018
Candida albicans is a leading cause of invasive fungal infections, with mortality rates of ~40%. Effective treatment is hindered by the paucity of antifungal drugs and the emergence of resistance.
Caplan, Tavia
core   +1 more source

Multicenter evaluation of low inoculum and a colorimetric assay for antifungal susceptibility testing of <i>Aspergillus fumigatus</i> to echinocandins with the EUCAST E.Def 9.4. [PDF]

J Clin Microbiol
Meletiadis J, Siopi M, Meinike Jørgensen K, Escribano P, Guinea J, Arendrup MC.   +5 more
europepmc   +1 more source

Mutational landscape and molecular bases of echinocandin resistance in Saccharomyces cerevisiae. [PDF]

Genetics
Durand R, Torbey AG, Giguere M, Pageau A, Dubé AK, Lagüe P, Landry CR.   +6 more
europepmc   +1 more source

Global surveillance of <i>Candida albicans</i>: MIC distributions, resistance patterns, and temporal trends from the Antimicrobial Testing Leadership and Surveillance program (2015-2024). [PDF]

Antimicrob Agents Chemother
Cai G, Zhang Z.
europepmc   +1 more source

Updated Genomic Epidemiologic Description of Candida (Candidozyma) auris, United States. [PDF]

Emerg Infect Dis
Parnell LA, Dos Santos AR, Forsberg K, Lyman M, Misas E, Gade L, Sexton DJ, Litvintseva AP, Chow NA.   +8 more
europepmc   +1 more source

The novel second-generation triterpenoid SCY-247 maintains <i>in vitro</i> and <i>in vivo</i> activity against resistant <i>Candida glabrata</i>. [PDF]

Antimicrob Agents Chemother
Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Patterson HP, Patterson TF.   +5 more
europepmc   +1 more source

Correction: Adaptive morphological changes link to poor clinical outcomes by conferring echinocandin tolerance in Candida tropicalis. [PDF]

PLoS Pathog
Wu Y, Zou Y, Dai Y, Lu H, Zhang W, Chang W, Wang Y, Nie Z, Wang Y, Jiang X.   +9 more
europepmc   +1 more source

Deciphering the multidrug resistance paradigm in <i>Candida auris</i>. [PDF]

Antimicrob Agents Chemother
Santana DJ, Cauldron NC, Rogers PD, Cuomo CA.   +3 more
europepmc   +1 more source

The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis. [PDF]

Infect Drug Resist
Zubovskaia A, Vazquez JA.
europepmc   +1 more source